主要文件

查看所有文档

N2126

新斯的明

Name: 新斯的明
Brand: SIGMA

别名:

N,N,N-三甲基-2-[(二甲氨基)甲酰氧基]苯铵甲磺酸盐

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₃H₂₂N₂O₆S

化学文摘社编号:

51-60-5

分子量:

334.39

NACRES:

NA.77

PubChem Substance ID:

24897553

UNSPSC Code:

12352200

EC Number:

200-109-5

MDL number:

MFCD00011796

Form:

solid

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

form

solid

Quality Level

100

storage temp.

−20°C

SMILES string

COS([O-])(=O)=O.CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C

InChI

1S/C12H19N2O2.CH4O4S/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;1-5-6(2,3)4/h6-9H,1-5H3;1H3,(H,2,3,4)/q+1;/p-1

InChI key

OSZNNLWOYWAHSS-UHFFFAOYSA-M

Gene Information

human ... ACHE(43)

说明

Biochem/physiol Actions

乙酰胆碱酯酶的可逆抑制剂；不能穿过血脑屏障。

类似于毒扁豆碱的乙酰胆碱酯酶的可逆抑制剂，但是不能穿过血脑屏障。

Still not finding the right product?

Explore all of our products under 新斯的明

pictograms

GHS06,GHS08

signalword

Danger

hcodes

H300,H315,H319,H334,H335

pcodes

P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 2 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Synthesis and efficacy of 1-[bis(4-fluorophenyl)-methyl]piperazine derivatives for acetylcholinesterase inhibition, as a stimulant of central cholinergic neurotransmission in Alzheimer's disease.

C T Sadashiva et al.

Bioorganic & medicinal chemistry letters, 16(15), 3932-3936 (2006-06-01)

The cholinergic hypothesis of Alzheimer's disease (AD) has spurred the development of numerous structural classes of compounds with different pharmacological profile aimed at increasing central cholinergic neurotransmission. Thus proving a symptomatic treatment for this disease are cholinomimetics with the pharmacological

Medical and surgical treatment for ocular myasthenia.

Michael Benatar et al.

The Cochrane database of systematic reviews, 12, CD005081-CD005081 (2012-12-14)

Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review

Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.

Qian-Sheng Yu et al.

Bioorganic & medicinal chemistry, 18(13), 4687-4693 (2010-07-16)

The N-monophenylcarbamate analogues of neostigmine methyl sulfate (6) and pyridostigmine bromide (8) together with their precursors (5), (7), and the N(1)-methylammonium analogues of (-)-phenserine (12), (-)-tolserine (14), (-)-cymserine (16) and (-)-phenethylcymserine (18) were synthesized to produce long-acting peripheral inhibitors of

查看所有相关文献

全球贸易项目编号

货号	GTIN
N2126-500MG	04061834110125
N2126-1G	04061835557950
N2126-5G	04061834110132